Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coronavirus Not Impacting Rx Manufacturing Supply Chain – Yet

Executive Summary

US FDA’s drug shortage team continues to check in with sponsors, but so far the infections and quarantines have not impacted drug production.

You may also be interested in...



US FDA Puts All China Drug Inspections On Hold Due To Coronavirus Outbreak

February and March inspections deferred unless any are deemed mission critical. China director remains behind as staff evacuate.

For Coronavirus, US FDA Is At The Podium But Not On The Task Force

The FDA is curiously not one of the HHS entities coordinating the US response to the outbreak, but must monitor for manufacturing disruptions and shortages, as well as approve new treatments and diagnostics.

Novel Virus Brings Novel Threats To Global Pharmaceutical Manufacturing

As coronavirus spreads into China’s manufacturing region, quarantines and travel restrictions challenge international flow of pharmaceuticals, ingredients and personnel.

Related Content

Topics

UsernamePublicRestriction

Register

PS141590

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel